Bioinformatics Solution Combines Artificial Intelligence, Maching Learning and Functional Testing to Elevate Precision Cancer Treatment
FOR IMMEDIATE RELEASE: Certis Oncology Solutions Announces Three Abstracts Accepted for Presentation at AACR Annual Meeting
Presentations to highlight the value of clinically relevant patient-derived xenograft (PDX) models for translational research and drug development
How to Overcome the Translation Gap in Cancer Research
Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope...
Innovations in Model Development - Upcoming Certis and Xtalks Webinar
In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to...
Mimicking the "Seed and Soil:" The State of PDX Models of Breast Cancer Metastases
Why do the quaintest analogies stick to biology’s most morbid phenomena? Look no further than English surgeon Stephen Paget’s “seed and soil” model for breast cancer metastasis for a prototypical example. In his 1889 publication in the Lancet, Paget...
Certis Oncology Solutions Releases New Cancer Model Database, BarneyOI
San Diego, CA — Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI™. This proprietary, online repository houses deep molecular characterization data for Certis’...
New Certis Whitepaper: Bringing Certainty to PDX Model Characterization
EXECUTIVE SUMMARY Patient-derived xenograft (PDX) models are indispensable for translational cancer research. However, public and private PDX tumor banks may lack standard quality controls, which may lead to genomic and transcriptomic...
Improving Drug Development and Glioblastoma Xenograft Models
Overcoming Glioblastoma Multiforme (GBM) Drug Development Challenges With Glioblastoma Xenograft Models Primary brain tumors are highly heterogeneous tumors that cause significant morbidity and mortality. An estimated 700,000 Americans are living...
Certis Oncology Solutions Awarded AAALAC Accreditation
San Diego, CA – Certis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International....
Developing Clinically Relevant Metastatic Colorectal Cancer Models: From Carcinogens to Xenografts
Colorectal cancer (CRC) is common and deadly, making up an estimated 7.9% of all new cancer cases and 8.7% of all cancer deaths in the U.S. last year.1 Cancer mortality often results from metastasis, which for colorectal cancer, happens frequently; ...